Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: This application provides: a nucleic acid construct characterized by comprising, in a mammalian artificial chromosome vector, a DNA sequence of interest, a matrix attachment region, and a replication origin, and by using for high expression of the DNA; a mammalian cell comprising the nucleic acid construct; and a method for high production of a protein encoded by the DNA of interest in the mammalian cell.

Abstract: The present invention provides fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity. The present invention also provides a method for producing fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity and a method for producing Tyr-Pro, each of which is characterized by comprising fermenting milk with a mushroom.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: The present invention aims at providing a disposable diaper having excellent maintainability of a surface space and capable of being easily produced.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid, N-methyl-2-pyrrolidone and a fluoride; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid and N-methyl-2-pyrrolidone; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.

Abstract: According to an aspect, a testing instrument that is used for testing an airway protection function includes: a pipe portion continuous from an inlet port to an outlet port, the pipe portion having a plurality of holes penetrating the pipe portion from an outer surface of the pipe portion to an inner surface of the pipe portion, the holes being provided for guiding a reagent gas mixture to the inside of the pipe portion; and a guide portion covering all of the holes to form a closed space and guiding the reagent gas mixture to the closed space from an inflow port.

Abstract: To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.

Abstract: In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid and N-methyl-2-pyrrolidone; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.

Abstract: The present invention has an object to provide a vaccinia virus expressing a foreign gene and capable of killing cancer cells, and a cancer therapy drug comprising the vaccinia virus. The present invention relates to a vaccinia virus, wherein a suicide gene as a foreign gene selected from the group consisting of cytosine deaminase (CD) gene, uracil phosphoribosyltransferase (UPRT) gene, and herpes simplex virus thymidine kinase (HSV-tk) gene is introduced.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid, N-methyl-2-pyrrolidone and a fluoride; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.

Abstract: The present invention provides fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity. The present invention also provides a method for producing fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity and a method for producing Tyr-Pro, each of which is characterized by comprising fermenting milk with a mushroom.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: This internal pressure loading system includes an internal pressure loading device and an information processing device. The internal pressure loading device is set at an inner face of a pipe, and includes a load meter which detects the load applied to the inner face of the pipe and a displacement meter which detects the deformation amount of the pipe. When the internal pressure loading device is expanded so as to increase the load to be detected by the load meter, the width of the pipe at which the displacement meter is located is reduced. On the basis of the load detected by the load meter and the deformation amount detected by the displacement meter, the information processing device evaluates the remaining strength of the pipe.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.

Abstract: This application provides: a non-human animal that comprises a mouse artificial chromosome comprising a human antibody heavy chain gene or gene locus, a human antibody light chain ? gene or gene locus, and/or a human antibody light chain ? gene or gene locus, and in which endogenous antibody genes or gene loci corresponding to at least 2 human antibody genes or gene loci have been knocked out, wherein the animal can be stably retained through generations and can produce human antibodies; a method for producing the non-human animal; and a method for producing human antibodies using the non-human animal.

Abstract: [Problem] To provide a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, and uterus adenomyosis. [Solution] To use an estrogen receptor ?-inhibiting ? partial agonist represented by the formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the afore-mentioned, as an active ingredient.

Abstract: It is an object of the present invention to provide utilization of a UCA1 gene that is a host regulatory factor that enhances replication and/or propagation of a vaccinia virus, in order to effectively carry out cancer virotherapy using the vaccinia virus. The present invention relates to: a method for predicting and evaluating the cancer therapeutic effects of a vaccinia virus, which comprises measuring the expression of a UCA1 gene in the cancer cells of a cancer patient, and then predicting that a vaccinia virus exhibits cancer therapeutic effects on the patient, when the UCA1 gene has been expressed therein; and a vaccinia virus into which a UCA1 gene has been expressibly introduced.